as Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month periods ended March 31, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“IAS 34”)– Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to “$” and “U.S. dollars” mean U.S. dollars and all references t ...

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 ...

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 ...

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the resignation of Mr. Bing Wang from his position of the Company with immediate effect, and the concomitant appointment of Mr. Arthur Stril as interim Chief Financial Officer, replacing Mr. Bing Wang. Mr. Stril joined Cellectis in 2018 as Vice President, Corporate Development, and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic collaboration and investment agreements with AstraZeneca • Cécile Chartier, Ph.D., appointed as a director of the Cellectis' Board of Directors • Drawdown of the second tranche of €15 million under the credit facility agreement entered into with the European Investment Bank (EIB) • Cash position of $156 million as of D ...

This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will present first d ...

Cellectis研究成果 - Cellectis是一家临床阶段的生物技术公司，利用其开创性的基因编辑平台开发拯救生命的细胞和基因疗法[1] - Cellectis在Molecular Therapy上发表了一篇新的研究论文，展示了TALEN介导的内含子编辑技术可以使造血干细胞和祖细胞（HSPCs）的转基因表达限制在髓系细胞系[1] - 该研究表明，通过在CD11b基因的第一个内含子中插入IDUA转基因，可以在髓系特异性地表达IDUA，而不影响CD11b内源表达[1] - Cellectis的内含子特异性基因插入方法可以有效限制所需转基因在髓系细胞系中的表达，避免其被干细胞或其他分化系细胞过度表达[1] - 通过编辑HSPC，可以在免疫缺陷小鼠的骨髓中观察到强健的植入，各种造血组织中的多系分化以及作为髓系细胞在大脑中的显著存在[1]

财务数据和关键指标变化 - 公司截至2023年9月30日的现金、现金等价物和受限现金为7,200万美元,较2022年12月31日的9,500万美元减少2,300万美元 [41][42] - 公司2023年前9个月的净亏损为5,800万美元,每股1.7美元,其中5,320万美元来自持续经营业务,较2022年前9个月的7,900万美元或每股1.74美元有所下降 [49] - 公司2023年前9个月的经调整净亏损为5,700万美元,每股1.05美元,较2022年前9个月的7,200万美元或每股1.58美元有所下降 [52] 各条业务线数据和关键指标变化 - 公司的三大临床试验BALLI-01、NATHALI-01和AMELI-01继续推进和招募患者 [28][34][38] - UCART22 P2制造工艺相比P1制造工艺更有效,在1百万细胞/公斤剂量下的初步响应率为67%,高于5倍剂量下P1制造工艺的50%响应率 [30][31][32] - UCART20x22在剂量水平1(50百万细胞/患者)下,3例患者全部在28天时达到响应,包括1例部分代谢响应和2例完全代谢响应 [35][36][37] 各个市场数据和关键指标变化 - 未提及 公司战略和发展方向和行业竞争 - 公司与阿斯利康达成战略合作,双方将在肿瘤、免疫和罕见疾病领域开发新的细胞和基因疗法 [11][12][13][15][16][17][18][19] - 公司将继续专注于推进BALLI-01、NATHALI-01和AMELI-01三大临床试验,并控制现金支出 [24] - 公司在制造工艺方面的专业知识和经验是成功的关键所在 [22][23] 管理层对经营环境和未来前景的评论 - 公司对与阿斯利康的合作以及自身临床项目的进展表示非常兴奋和乐观 [11][19][55] - 公司相信自身的产品候选药物、技术和内部制造能力将推动细胞和基因疗法的发展,使公司处于该领域的前沿 [56] 问答环节重要的提问和回答 问题1 **Dev Prasad 提问** 询问UCART20x22在剂量水平1的结果是否会推动扩大试验点和进一步剂量递增 [59][60] **Mark Frattini 回答** 公司计划进行剂量递增,具体的剂量水平和最大耐受剂量将根据临床数据确定 [60] 问题2 **Unidentified Analyst 提问** 询问UCART123的时间线以及UCART22是否可以直接进入关键性试验 [63][64] **Mark Frattini 回答** UCART123将在明年某个时候公布临床数据,UCART22则将继续进行剂量递增研究 [66][67] 问题3 **Unidentified Analyst 提问** 询问阿斯利康选择目标的时间安排以及未被选择的目标是否会归还给公司 [70][71] **Arthur Stril 回答** 阿斯利康将从25个目标中选择最多10个候选产品,未被选择的目标将归还给公司 [71]

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")– Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to "$" and "U.S. dollars" mean U.S. dollars and all r ...